Industry Fears 'Double Taxation' For Combo Products, Device Kits
This article was originally published in The Pink Sheet Daily
IRS is developing guidance to implement a 2.3% device tax created by the health care reform law and set to go into effect on Jan. 1, 2013. But companies selling drug-device combination products are concerned that they could be liable for both the device tax and a prescription drug manufacturer fee also established in the 2010 reforms.
You may also be interested in...
Hospitals and group purchasers are pressing the Internal Revenue Service to develop regulations that would make it more difficult for medical technology firms to pass the costs of the upcoming device excise tax onto customers.
The Internal Revenue Service should be flexible in deciding which medical devices will be exempt from a new excise tax, AdvaMed says.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.